Alternatively, B-Raf, and its downstream signaling pathway through MAP kinases, directly promotes cell proliferation leading in melanomas, as evidenced by the positive clinical trials for B-Raf inhibitor drugs Dabrafenib and Vemurafenib [13, 14]. This evidence concerns the gene BRAF and melanoma.